China's Connect Biopharma gains 8% on debut after $191m US IPO
Connect Biopharma, a China-headquartered drug developer specializing in treatments for T cell-driven inflammatory diseases, gained 8.8% on debut following a $191.3 million US IPO.
The company sold 11.25 million American Depository Shares (ADS) – having upsized the offering from 9.38 million shares – for $17 apiece, according to a filing. There is an overallotment option of up...
More on Greater China
Latest News
China AI drug discovery platform StoneWise raises $100m
StoneWise, a Chinese biotech start-up that uses artificial intelligence (AI) technology to develop new drugs, has raised $100 million in Series B funding across two tranches.
Media SPAC legitimizes MENA for Asia investors
The imminent US listing of a Middle East and North Africa (MENA) media app via a special purpose acquisition company (SPAC) is helping legitimize the region for Asian private equity.
Australia's Quadrant loses growth fund head
Justin Ryan, a managing partner at Quadrant Private Equity and latterly head of the Australian firm’s growth strategy, is stepping back from day-to-day investment activity.
KKR joins $61m round for Japan's Netstars
KKR has contributed JPY4 billion ($37 million) to a JPY6.6 billion funding round for Netstars, a Japanese QR code payment gateway operator. SIG and Lun Partners, a Hong Kong-based global financial technology investor, also took part.